3-(2-methoxy-phenyl)-3-oxo-propionic acid | 76103-94-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3-(2-methoxy-phenyl)-3-oxo-propionic acid
• 英文别名: 3-(2-Methoxy-phenyl)-3-oxo-propionsaeure；2-Methoxy-benzoylessigsaeure；o-Methoxybenzoylacetic acid；3-(2-methoxyphenyl)-3-oxopropanoic acid
• CAS: 76103-94-1
• 化学式: C₁₀H₁₀O₄
• 分子量: 194.187
• InChiKey: SMLRWMFUJLCTFI-UHFFFAOYSA-N

物化性质

• 沸点：
  382.4±22.0 °C(Predicted)
• 密度：
  1.243±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  63.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-(2-methoxy-phenyl)-3-oxo-propionic acid 在 三氟甲磺酸酐 作用下， 以 二氯甲烷 为溶剂， 反应 48.0h， 以41%的产率得到2,6-bis(2-methoxyphenyl)-4H-pyran-4-one
  参考文献：
  名称：

  β-酮酸的脱羧缩合反应合成γ-吡喃酮

  摘要：

  摘要该手稿描述了由β-酮酸聚合合成芳基和烷基二取代的γ-吡喃酮。反应在三氟甲磺酸酐的存在下通过原料的空前的脱羧自动缩合而进行。在此，报道了这种转变的范围和局限性。 图形概要

  DOI：

  10.1007/s00706-016-1851-2
• 作为产物：
  描述：

  (2-甲氧基苯甲酰)乙酸乙酯 在 sodium hydroxide 作用下， 以 水 为溶剂， 以94%的产率得到3-(2-methoxy-phenyl)-3-oxo-propionic acid
  参考文献：
  名称：

  β-酮酸的脱羧缩合反应合成γ-吡喃酮

  摘要：

  摘要该手稿描述了由β-酮酸聚合合成芳基和烷基二取代的γ-吡喃酮。反应在三氟甲磺酸酐的存在下通过原料的空前的脱羧自动缩合而进行。在此，报道了这种转变的范围和局限性。 图形概要

  DOI：

  10.1007/s00706-016-1851-2

文献信息

• [EN] NEW THIENOPYRIMIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM<br/>[FR] NOUVEAUX DÉRIVÉS DE THIÉNOPYRIMIDINE, PROCÉDÉ POUR LEUR PRÉPARATION ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
  申请人：SERVIER LAB

  公开号：WO2015097123A1

  公开（公告）日：2015-07-02

  Compounds of formula (I): wherein R1, R2, R3, R4, R5, R6, R7, R12, X, A and n are as defined in the description.

  式（I）的化合物：其中R1、R2、R3、R4、R5、R6、R7、R12、X、A和n的定义如描述中所述。
• [EN] AMINOMETHYLENE PYRAZOLONES WITH THERAPEUTIC ACTIVITY<br/>[FR] PYRAZOLONES AMINOMÉTHYLÈNE À ACTIVITÉ THÉRAPEUTIQUE
  申请人：COMPOUND HANDLING B V

  公开号：WO2013131931A1

  公开（公告）日：2013-09-12

  A compound having the structure according to formula III wherein: X is NH or S;R1 is H or (1C-4C)alkyl;R2 is (1C-4C)alkyl, phenyl or a monocyclic aromatic ring having one or more N-, O-or S-atoms in the ring, which alkyl, phenyl or aromatic ring is optionally substituted with one or more groups selected from (1C-4C)alkyl, (1C-4C)alkyloxy, halo(1C-4C)alkyl, halo(1C-4C)alkyloxy, phenyloxy, phenylthio, halogen, or nitro;R3 and R4 are each independently H, (1C-6C)alkyl, (2C-6C) alkenyl, (2C-6C)alkynyl, cyano, (3C-6C)cycloalkyl, phenyl, a monocyclic aromatic ring having one or more N-, O- or S-atoms in the ring, a monocyclic non-aromatic ring having one or more N-, O- or S-atoms in the ring, each optionally substituted with hydroxyl, (1C-4C)alkoxy, phenyl, cycloalkyl, piperidyl, piperazinyl, furyl, thienyl, pirazinyl, pyrrolyl, 2H-pyrrolyl, pyrazolyl, isoxazolyl, isothiazolyl, pyrrolidonyl, pyrrolinyl, imidazolinyl, imidazolyl, a monocyclic aromatic ring having one or more N-, O- or S- atoms in the ring, whereby each of these optional substituents is optionally further substituted with (1C-4C)alkyl, (1C-4C)alkyloxy, halo(1C-4C)alkyl, halo(1C-4C)alkyloxy, halogen, nitro or (1C-2C)dioxol forming a ring;or R3 and R4 form together pyrrolyl, imidazolyl, pyrazolyl, pyrrolidinyl, pyrrolinylimidazolidinyl, imidazolinyl, piperidyl, piperazinylmorpholinyl, each optionally substituted with (1C-6C)alkyl, phenyl(1C-4C)alkyl, phenylketo(1C-4C)alkyl; R5 is H, Cl, F, Br, Me, NO2, t-butyl, OCF3, OCH3, CF3; R6 is H, (1C-4C)alkyl, (1C-4C)alkyloxy, halo(1C-4C)alkyl, halo(1C-4C)alkyloxy, nitro or halogen;R7 is H,F, Cl, Br, Me, NO2, t-butyl, OCF3, OCH3, CF3; or pharmaceutically acceptable addition salts thereof for use in treatments of carcinoma, in particular to delay, prevent or reverse metastasis in prostate cancer.

  具有根据式III的结构的化合物，其中：X为NH或S；R1为H或(1C-4C)烷基；R2为(1C-4C)烷基、苯基或具有环中一个或多个N、O或S原子的单环芳香环，该烷基、苯基或芳香环可以选择地被一个或多个来自(1C-4C)烷基、(1C-4C)烷氧基、卤代(1C-4C)烷基、卤代(1C-4C)烷氧基、苯氧基、苯硫基、卤素或硝基的基团取代；R3和R4分别独立地为H、(1C-6C)烷基、(2C-6C)烯基、(2C-6C)炔基、氰基、(3C-6C)环烷基、苯基、具有环中一个或多个N、O或S原子的单环芳香环、具有环中一个或多个N、O或S原子的单环非芳香环，每个可以选择地被羟基、(1C-4C)烷氧基、苯基、环烷基、哌啶基、哌嗪基、呋喃基、噻吩基、吡嗪基、吡咯基、2H-吡咯基、吡唑基、异噁唑基、异硫唑基、吡咯烷酰基、吡咯烯基、咪唑啉基、咪唑啉基咪唑啉基、咪唑啉基、哌啶基、哌嗪基吗啉基，每个可以选择地进一步被(1C-4C)烷基、(1C-4C)烷氧基、卤代(1C-4C)烷基、卤代(1C-4C)烷氧基、卤素、硝基或(1C-2C)二氧杂环己基取代形成环；或者R3和R4共同形成吡咯基、咪唑基、吡唑基、吡咯烷基、吡咯烯基、咪唑啉基、哌啶基、哌嗪基吗啉基，每个可以选择地被(1C-6C)烷基、苯基(1C-4C)烷基、苯基酮(1C-4C)烷基取代；R5为H、Cl、F、Br、Me、NO2、叔丁基、OCF3、OCH3、CF3；R6为H、(1C-4C)烷基、(1C-4C)烷氧基、卤代(1C-4C)烷基、卤代(1C-4C)烷氧基、硝基或卤素；R7为H、F、Cl、Br、Me、NO2、叔丁基、OCF3、OCH3、CF3；或其在治疗癌症，特别是延迟、预防或逆转前列腺癌转移方面的药学上可接受的加合物盐。
• Aminomethylene pyrazolones with therapeutic activity
  申请人：Compound Handling B.V.

  公开号：EP2636673A1

  公开（公告）日：2013-09-11

  The invention provides for a compound having the structure according to formula I wherein: X is NH or S; R1 is H or (1C-4C)alkyl; R2 is (1C-4C)alkyl, phenyl or a monocyclic aromatic ring having one or more N-, O- or S- atoms in the ring, which alkyl, phenyl or aromatic ring is optionally substituted with one or more groups selected from (1C-4C)alkyl, (1C-4C)alkyloxy, halo(1C-4C)alkyl, halo(1C-4C)alkyloxy, phenyloxy , phenylthio, halogen, or nitro; R3 and R4 are each independently H, (1C-6C)alkyl, (2C-6C) alkenyl, (2C-6C)alkynyl, cyano, (3C-6C)cycloalkyl, phenyl, a monocyclic aromatic ring having one or more N-, O- or S- atoms in the ring, a monocyclic non-aromatic ring having one or more N-, O- or S- atoms in the ring, each optionally further substituted with hydroxyl, (1C-4C)alkoxy, phenyl, cycloalkyl, piperidyl, piperazinyl, furyl, thienyl, pirazinyl, pyrrolyl, 2H-pyrrolyl, pyrazolyl, isoxazolyl, isothiazolyl, pyrrolidonyl, pyrrolinyl, imidazolinyl, imidazolyl, a monocyclic aromatic ring having one or more N-, O- or S-atoms in the ring, whereby each of these optional substituents is optionally further substituted with (1 C-4C)alkyl, (1 C-4C)alkyloxy, halo(1 C-4C)alkyl, halo(1 C-4C)alkyloxy, halogen, nitro or (1 C-2C)dioxol forming a ring; or R3 and R4 form together pyrrolyl, imidazolyl, pyrazolyl, pyrrolidinyl, pyrrolinylimidazolidinyl, imidazolinyl, piperidyl, piperazinylmorpholinyl, each optionally substituted with (1 C-6C)alkyl, phenyl(1 C-4C)alkyl, phenylketo(1C-4C)alkyl; R5 is H or CF3; R6 is (1 C-4C)alkyl, (1 C-4C)alkyloxy, halo(1 C-4C)alkyl, halo(1 C-4C)alkyloxy, nitro or halogen; for use in treatments of carcinoma, in particular to delay, prevent or reverse metastasis in prostate cancer.

  该发明提供了一种具有以下结构的化合物，符合以下公式I： 其中： X为NH或S；R1为H或(1C-4C)烷基；R2为(1C-4C)烷基、苯基或具有环中一个或多个N、O或S原子的单环芳香环，该烷基、苯基或芳香环可以选择性地被一个或多个来自(1C-4C)烷基、(1C-4C)烷氧基、卤代(1C-4C)烷基、卤代(1C-4C)烷氧基、苯氧基、苯硫基、卤素或硝基的基团取代；R3和R4分别独立地为H、(1C-6C)烷基、(2C-6C)烯基、(2C-6C)炔基、氰基、(3C-6C)环烷基、苯基、具有环中一个或多个N、O或S原子的单环芳香环、具有环中一个或多个N、O或S原子的单环非芳香环，每个基团可以选择性地进一步被羟基、(1C-4C)烷氧基、苯基、环烷基、哌啶基、哌嗪基、呋喃基、噻吩基、吡嗪基、吡咯基、2H-吡咯基、吡唑基、异噁唑基、异硫唑基、吡咯烷酰基、吡咯烯基、咪唑啉基、咪唑啉基咪唑啉基、咪唑啉基、哌啶基、哌嗪基吗啉基，每个基团可以选择性地进一步被(1C-4C)烷基、(1C-4C)烷氧基、卤代(1C-4C)烷基、卤代(1C-4C)烷氧基、卤素、硝基或(1C-2C)二氧杂环己基取代形成环；或者R3和R4共同形成吡咯基、咪唑基、吡唑基、吡咯烷基、吡咯烯基、咪唑啉基、哌啶基、哌嗪基吗啉基，每个基团可以选择性地被(1C-6C)烷基、苯基(1C-4C)烷基、苯基酮(1C-4C)烷基取代；R5为H或CF3；R6为(1C-4C)烷基、(1C-4C)烷氧基、卤代(1C-4C)烷基、卤代(1C-4C)烷氧基、硝基或卤素；用于治疗癌症，特别是用于延迟、预防或逆转前列腺癌的转移。
• [EN] KV1.3 INHIBITORS AND THEIR MEDICAL APPLICATION<br/>[FR] INHIBITEURS DE KV1.3 ET LEUR APPLICATION MÉDICALE
  申请人：4SC DISCOVERY GMBH

  公开号：WO2016146583A1

  公开（公告）日：2016-09-22

  The present invention relates to a compound of the general formula (II) or a salt or solvate thereof, as well as medical uses involving them, wherein A1 is selected from the group consisting of N and C-R8; A2 is selected from the group consisting of N and C-R3, A3 is selected from the group consisting of N and C-R9; A4 and A5 and A6 are independently selected from the group consisting of N and C-R1; R1 is selected from the group consisting of hydrogen, (C1-C3)alkyl, halogen, (C1-C3)alkoxy, and (C1-C3)haloalkyl; R2 is selected from the group consisting of hydrogen, halogen, and (C1-C3)alkyl; R3 is selected from the group consisting of hydrogen, (C1-C3)alkyl, NR4R5, (C1-C3)alkyl- NR4R5, and cyano, wherein R4 and R5 are independently selected from the group consisting of hydrogen, (C3-C5)cycloalkyl, (C3-C5)heterocycloalkyl and (C1-C3)alkyl, or R4 and R5 together with the nitrogen atom to which they are attached form a 5- to 7-membered heterocyclic ring optionally comprising in addition to the aforementioned nitrogen atom a further heteroatom group selected from the group consisting of O and NR6, wherein R6 is selected from the group consisting of hydrogen, methyl, acetyl and formyl; Y is selected from the group consisting of O and S; R8 is selected from the group consisting of (C1-C4)alkyl, (C3-C5)cycloalkyl and (C3-C5)heterocycloalkyl; and R9 is selected from the group consisting of hydrogen, (C1-C3)alkyl and (C1-C3)alkoxy; wherein certain particular compounds are excluded py proviso, and methods for producing such compounds.

  本发明涉及一般式（II）的化合物或其盐或溶剂络合物，以及涉及它们的医药用途，其中A1从N和C-R8组成的组中选择；A2从N和C-R3组成的组中选择，A3从N和C-R9组成的组中选择；A4、A5和A6独立地从N和C-R1组成的组中选择；R1从氢、（C1-C3）烷基、卤素、（C1-C3）烷氧基和（C1-C3）卤代烷基组成的组中选择；R2从氢、卤素和（C1-C3）烷基组成的组中选择；R3从氢、（C1-C3）烷基、NR4R5、（C1-C3）烷基-NR4R5和氰基组成的组中选择，其中R4和R5独立地从氢、（C3-C5）环烷基、（C3-C5）杂环烷基和（C1-C3）烷基组成的组中选择，或者R4和R5与它们连接的氮原子一起形成一个5至7元杂环，该环可选地包括除上述氮原子外进一步选择的O和NR6等杂原子基团，其中R6从氢、甲基、乙酰基和甲酰基组成的组中选择；Y从O和S组成的组中选择；R8从（C1-C4）烷基、（C3-C5）环烷基和（C3-C5）杂环烷基组成的组中选择；R9从氢、（C1-C3）烷基和（C1-C3）烷氧基组成的组中选择；其中特定的某些化合物受限制，以及生产这种化合物的方法。
• Organocatalytic decarboxylative aldol reaction of β-ketoacids with α-ketophosphonates en route to the enantioselective synthesis of tertiary α-hydroxyphosphonates
  作者：Ganga B. Vamisetti、Raghunath Chowdhury、Sunil K. Ghosh

  DOI：10.1039/c7ob00796e

  日期：——

  (aroylacetic acids) with α-ketophosphonates that produces a quaternary chiral centre has been developed. A quinidine based bifunctional urea derivative was identified as the preferred catalyst affording γ-aroyl tertiary α-hydroxyphosphonates in good yield and enantioselectivity. The 31P NMR spectroscopic study was performed to shed light on the reaction mechanism.

  已经开发了β-酮酸（芳酰基乙酸）与α-酮膦酸酯的不对称有机催化的脱羧醛醇缩合反应的第一个实例，其产生季手性中心。已鉴定出基于奎尼丁的双官能脲衍生物是优选的催化剂，其以良好的收率和对映选择性提供γ-芳酰基叔α-羟基膦酸酯。进行31 P NMR光谱研究以阐明反应机理。